Aceso Life Science Group Income Statement

Financials in millions HKD. Fiscal year is April - March.

Millions HKD. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '25 Sep 30, 2025	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021
Total Interest Expense	107	124	143	140	154	191
Net Interest Income	-107	-124	-143	-140	-154	-191
Other Revenue	201	195	228	312	315	346
Revenue Before Loan Losses	94	71	85	172	161	155
Provision for Loan Losses	150	142	74	-35	-9	284
Revenue	-56	-71	11	207	170	-129
Revenue Growth (YoY)	-	-	-94.69%	21.77%	-	-
Cost of Services Provided	251	219	235	294	299	288
Total Operating Expenses	251	219	235	297	306	337
Operating Income	-307	-290	-224	-90	-136	-466
Earnings From Equity Investments	-98	-94	-325	-209	-74	288
Currency Exchange Gain (Loss)	-5	-6	-4	12	9	5
EBT Excluding Unusual Items	-424	-378	-465	-193	-144	-75
Gain (Loss) on Sale of Investments	-300	-29	-242	-81	-510	-157
Impairment of Goodwill	-	-	-	-	-	-13
Other Unusual Items	-	-	-	60	9	-1
Pretax Income	-521	-1,027	-823	-213	-555	-323
Income Tax Expense	-4	-10	-14	-5	41	25
Earnings From Continuing Ops.	-517	-1,017	-809	-208	-596	-348
Minority Interest in Earnings	122	122	347	-56	226	-28
Net Income	-372	-895	-462	-264	-370	-376
Net Income to Common	-372	-895	-462	-264	-370	-376
Shares Outstanding (Basic)	7,285	7,197	7,274	7,318	7,203	6,559
Shares Outstanding (Diluted)	7,285	7,197	7,274	7,318	7,439	7,014
Shares Change (YoY)	0.98%	-1.06%	-0.60%	-1.63%	6.06%	21.39%
EPS (Basic)	-0.05	-0.12	-0.06	-0.04	-0.05	-0.06
EPS (Diluted)	-0.05	-0.12	-0.06	-0.04	-0.06	-0.06
Free Cash Flow	116	15	-48	190	259	164
Free Cash Flow Per Share	0.02	0.00	-0.01	0.03	0.04	0.02
Operating Margin	-	-	-2036.36%	-43.48%	-80.00%	-
Profit Margin	-	-	-4200.00%	-127.54%	-217.65%	-
Free Cash Flow Margin	-	-	-436.36%	91.79%	152.35%	-